I am a
Home I AM A Search Login

Papers of the Week

2022 Aug 19

Dermatol Ther (Heidelb)

Dupilumab Treatment of Atopic Dermatitis in Routine Clinical Care: Baseline Characteristics of Patients in the PROLEAD Prospective, Observational Study.


Thaçi D, Bauer A, von Kiedrowski R, Schenck F, Ertner K, Möller S, Fait A, Bastian M, Augustin M
Dermatol Ther (Heidelb). 2022 Aug 19.
PMID: 35984627.


Dupilumab is the first biologic licensed to treat patients with moderate-to-severe atopic dermatitis (AD) who require systemic therapy. PROLEAD was designed to document the real-world effectiveness and safety of dupilumab in patients with moderate-to-severe AD. The present study aims to describe the baseline characteristics of patients treated with dupilumab in Germany.